Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They currently have a $26.00 price objective on the stock. Chardan Capital’s price objective points to a potential upside of 201.27% from the company’s previous close.

Several other equities research analysts also recently issued reports on the company. Barclays began coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Royal Bank Of Canada reissued an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Finally, Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.67.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT traded up $0.07 during midday trading on Thursday, reaching $8.63. 136,503 shares of the stock were exchanged, compared to its average volume of 725,569. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $12.34. The company has a market capitalization of $493.03 million, a price-to-earnings ratio of -2.32 and a beta of 2.99. The business has a 50-day simple moving average of $8.70 and a two-hundred day simple moving average of $9.09.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Friday, March 20th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of ($0.53) by $0.96. The business had revenue of $85.09 million for the quarter, compared to the consensus estimate of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. Equities research analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Rockefeller Capital Management L.P. raised its position in 4D Molecular Therapeutics by 14,343.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 18,054 shares of the company’s stock valued at $135,000 after buying an additional 17,929 shares during the last quarter. Invesco Ltd. boosted its position in 4D Molecular Therapeutics by 21.0% during the 4th quarter. Invesco Ltd. now owns 153,142 shares of the company’s stock worth $1,149,000 after acquiring an additional 26,563 shares during the last quarter. XTX Topco Ltd boosted its position in 4D Molecular Therapeutics by 62.6% during the 4th quarter. XTX Topco Ltd now owns 65,022 shares of the company’s stock worth $488,000 after acquiring an additional 25,039 shares during the last quarter. Virtus Investment Advisers LLC bought a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $184,000. Finally, Susquehanna Portfolio Strategies LLC bought a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $77,000. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.